Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Living or deceased donor renal allograft
Men and women, 18 to 70 years old
Subjects who have received a de novo kidney transplant, who have completed the initial study treatment through Month 12, and are willing to sign informed consent will be eligible to continue into the long term extension phase
You may not be if
Pregnant or breastfeeding women
Epstein Barr Virus (EBV) negative serology
First time renal transplant with panel reactive antibody (PRA) ≥ 50% or retransplantation with PRA \> 30%
Graft loss due to AR
Positive T-cell or B-cell crossmatch
Recipients/donors with HIV or hepatitis B/C
Active tuberculosis (TB)
Immunosuppressive therapy within 1 year of enrollment
UNOS ECD organs will be excluded
Body mass index (BMI) \> 35 kg/m²
Subjects who have developed any malignancy (other than non-melanoma skin cancer) or other medical condition that, in the investigator's opinion, should not be treated with an experimental immunosuppressive drug like belatacept
Clareo Health | A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
